Biomarkers that discriminate multiple myeloma patients with or without skeletal involvement detected using SELDI-TOF mass spectrometry and statistical and machine learning tools.

Department of Orthopaedic Surgery, Center for Orthopaedic Research, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Disease markers (Impact Factor: 2.17). 02/2006; 22(4):245-55. DOI: 10.1155/2006/728296
Source: PubMed

ABSTRACT Multiple Myeloma (MM) is a severely debilitating neoplastic disease of B cell origin, with the primary source of morbidity and mortality associated with unrestrained bone destruction. Surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) was used to screen for potential biomarkers indicative of skeletal involvement in patients with MM. Serum samples from 48 MM patients, 24 with more than three bone lesions and 24 with no evidence of bone lesions were fractionated and analyzed in duplicate using copper ion loaded immobilized metal affinity SELDI chip arrays. The spectra obtained were compiled, normalized, and mass peaks with mass-to-charge ratios (m/z) between 2000 and 20,000 Da identified. Peak information from all fractions was combined together and analyzed using univariate statistics, as well as a linear, partial least squares discriminant analysis (PLS-DA), and a non-linear, random forest (RF), classification algorithm. The PLS-DA model resulted in prediction accuracy between 96-100%, while the RF model was able to achieve a specificity and sensitivity of 87.5% each. Both models as well as multiple comparison adjusted univariate analysis identified a set of four peaks that were the most discriminating between the two groups of patients and hold promise as potential biomarkers for future diagnostic and/or therapeutic purposes.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer bone metastasis (BM) is a complication that significantly compromises patient survival due, in part, to the lack of disease-specific biomarkers that allow early and accurate diagnosis Using mass spectrometry protein profiling, plasma samples were screened from 3 independent breast cancer patient cohorts with and without clinical evidence of bone metastasis. The results identified 13 biomarkers that classified all 110 patients with a sensitivity of 91% and specificity of 93% [receiver operating characteristics area under the curve (AUC=1.00)]. The most discriminatory protein was subsequently identified as a unique 12-48aa peptide fragment of parathyroid hormone-related protein (PTHrP). PTHrP(12-48) was significantly increased in BM patients plasma compared with patients without BM (p<0.0001). Logistic regression models were used to evaluate the diagnostic potential of PTHrP(12-48) as a single biomarker or in combination with the measurement of the clinical marker N-telopeptide of type I collagen (NTx). The PTHrP(12-48) and NTx logistic regression models were not significantly different and classified the patient groups with high accuracy (AUC=0.85 and 0.95) respectively. Interestingly, in combination with serum NTx, the plasma concentration of PTHrP(12-48) increased diagnostic specificity and accuracy (AUC=0.99). These data demonstrate that PTHrP(12-48) circulates in breast cancer patient plasma and is a novel and predictive biomarker of breast cancer BM. Importantly, the clinical measurement of PTHrP(12-48) in combination with NTx improves the detection of breast cancer BM. In summary, we present the first validated, plasma biomarker signature for diagnosis of breast cancer BM that may improve the early diagnosis of high-risk individuals.
    Cancer Epidemiology Biomarkers & Prevention 03/2013; 22(5). DOI:10.1158/1055-9965.EPI-12-1318-T · 4.32 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The discovery of biomarkers unique to multiple myeloma (MM) is of great importance to clinical practice. This study was designed to identify serum tumor marker candidates of MM in the mass range of 700-10000 Da. Serum samples from 48 MM patients and 74 healthy controls were collected and classified into a training dataset (MM/controls: 26/26) and a testing dataset (MM/controls: 22/48). Weak cation exchange magnetic beads, MALDI-TOF MS and analytic software in the CLINPROT system were used to do serum sample pre-fractionation, data acquisition and data analysis. Peak statistics were performed using Welch's t test. Mass spectra from the two model generation cohorts in the training dataset were analyzed by the Supervised Neural Network Algorithm (SNNA) in ClinProTools((TM)) to identify the mass peaks with the highest separation power. The resulting diagnostic model was subsequently validated in the testing dataset. A total of 89 discriminating mass peaks were detected by ClinProTools((TM)) in the range of 700-10000 Da using a signal to noise threshold of 3.0. Of these, 49 peaks had statistical significance (P < 0.0001) and four peaks with the highest separation power were picked up by SNNA to form a diagnostic model. This model achieved high sensitivity (86.36 %) and specificity (87.5 %) in the validation in the testing dataset. Using CLINPROT system and MB-WCX we found four novel biomarker candidates. The diagnostic model built by the four peaks achieved high sensitivity and specificity in validation. CLINPROT system is a powerful and reliable tool for clinical proteomic research.
    International journal of hematology 04/2012; 95(6):668-74. DOI:10.1007/s12185-012-1080-3 · 1.68 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Early diagnosis of bone metastases is crucial in order to determine the prognosis and optimize therapy. Traditional methods, such as plain radiography or bone scintigraphy, lack either sensitivity or specificity. Computed tomography (CT) is quite sensitive, however, its ability to detect early deposits is limited. FDG {PET – CT} scan detects metastatic bone disease before occurrence of osteoblastic activity. Magnetic resonance imaging (MRI) has been shown to be the most sensitive imaging technique, with a sensitivity of up to 100% reported and its specificity was reported to reach 97%. MRI of bone metastases depends on the degree of bone resorption or deposition. The lesion pattern may be lytic, sclerotic or mixed. Adequate characterization of lesions depends on fat and water distribution in bone marrow, normal bone trabeculae, tissue vascularization, cell density and bone oedema. T1 – weighted spin – echo (SE), T2 – weighted turbo SE and STIR are the sequences most frequently used. Gadolinium enhancement demonstrates areas of greatest tumor activity. Diffusion-weighted imaging helps in the discrimination between benign and malignant vertebral body compression fractures. Whole-body MRI is a feasible alternative to bone scintigraphy in evaluating the entire skeleton. MRI is the modality of choice for the evaluation of bone metastases. It’s a non invasive technique, presenting great tissue contrast, without the use of ionizing radiation. MRI depicts metastases in an early stage and provides additional information about tumor extent. It helps in tumor screening and staging, as well as in the control of the disease progression and the post treatment evaluation.
    12/2008: pages 163-181;


Available from